Aniling is a clinical-stage biotech company developing solutions based on next-generation genomic and epigenomic sequencing (NGS) methods for precision oncology.

Aniling was founded in 2014 as a spin-off from the Institute of Predictive and Personalised Medicine of Cancer (IMPPC), currently part of the Germans Trias i Pujol Biomedical Research Institute (IGTP), and is based at the Can Ruti Campus in Badalona (Barcelona, Spain).